Zacks Rating on Charles River Laboratories International (CRL)

Charles River Laboratories International (CRL) : Zacks Investment Research ranks Charles River Laboratories International (CRL) as 2, which is a Buy recommendation. 7 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 more believe that the stock has more downside risks, hence they propose a Strong Sell. A total of 5 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 13 research analysts is 2.08, which indicates as a Buy.

Charles River Laboratories International (CRL) : The most positive equity analysts on Charles River Laboratories International (CRL) expects the shares to touch $100, whereas, the least positive believes that the stock will trade at $65 in the short term. The company is covered by 8 Wall Street Brokerage Firms. The average price target for shares are $90.63 with an expected fluctuation of $12.19 from the mean.


Shares of Charles River Laboratories International, Inc. appreciated by 0.24% during the last five trading days but lost 3.24% on a 4-week basis. Charles River Laboratories International, Inc. has dropped 2.18% during the last 3-month period . Year-to-Date the stock performance stands at 3.93%. Charles River Laboratories International (NYSE:CRL): On Tuesdays trading session , Opening price of the stock was $83.84 with an intraday high of $84.59. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $83.34. However, the stock managed to close at $83.55, a loss of 0.05% for the day. On the previous day, the stock had closed at $83.59. The total traded volume of the day was 348,690 shares.

Charles River Laboratories International, Inc. is a full service, early stage contract research company. The Company offers research models for the research and development of new drugs, devices and therapies. It develops a portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP that support the clients from target identification through preclinical development. The Company operates through three segments: Research Models and Services (RMS), which supplies research models to the drug development industry; Discovery and Safety Assessment (DSA), which provides services that enables the clients to outsource their drug discovery research, critical, regulatory-required safety assessment testing and related drug discovery and development activities, and Manufacturing Support (Manufacturing), which is involved in the production and release of products manufactured by the clients.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.